CytoCore Inc. (OTCMKTS:MDIT) Director William Austin Iv Lewis bought 10,666,667 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was purchased at an average price of $0.08 per share, for a total transaction of $853,333.36. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of CytoCore Inc. (OTCMKTS:MDIT) opened at $0.19 on Tuesday. CytoCore Inc. has a 12 month low of $0.11 and a 12 month high of $0.88. The stock has a market capitalization of $5.34, a P/E ratio of -0.88 and a beta of -1.09. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.69 and a current ratio of 1.54.

CytoCore (OTCMKTS:MDIT) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. CytoCore had a negative return on equity of 71.60% and a negative net margin of 76.67%.

Separately, ValuEngine upgraded CytoCore from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at

About CytoCore

MEDITE Cancer Diagnostics, Inc (MEDITE), formerly CytoCore, Inc, is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases.

Receive News & Ratings for CytoCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoCore and related companies with's FREE daily email newsletter.